A B S T R A C T Platelet-type von Willebrand disease (vWD) and pseudo-vWD are two recently described intrinsic platelet defects characterized by enhanced ristocetin-induced agglutination in platelet-rich plasma. A similar finding is also typical of type IIB vWD, where it has been related to a von Willebrand factor (vWF) rather than a platelet abnormality. Platelet aggregation induced by unmodified human vWF in the absence of other stimuli has been reported in pseudovWD. In this study we demonstrate that vWF induces aggregation in platelet-type but not type IIB vWD. Aggregation is observed when normal plasma cryoprecipitate or purified vWF are added to platelet-rich plasma. Cryoprecipitate also aggregates washed platelets, although at higher concentrations than required for platelet-rich plasma. Purified vWF, however, induces significant aggregation of washed platelets only when plasma is added. EDTA inhibits vWF-induced aggregation. Its 
sized multimers of vWF become associated with platelets. Both aggregation and binding exhibit a similar vWF concentration dependence, suggesting that a correlation exists between these two events. Removal of ADP by appropriate consuming systems is without effect upon such binding or upon vWF-induced aggregation. Thrombin-induced 1251-vWF binding to washed platelets is normal in platelet-type as well as type IIB vWD. These results demonstrate that a specific binding site for unmodified human vWF is exposed on unstimulated platelets in platelet-type vWD. The relatively high vWF concentrations required for aggregation and binding may explain the lack of significant in vivo aggregation and thrombocytopenia in these patients. Moreover, these studies provide additional evidence that platelet-type and type IIB vWD are different diseases with distinct pathogeneses. INTRODUCTION von Willebrand factor (vWF)' is a large multimeric glycoprotein that circulates in plasma complexed with the Factor VIII procoagulant activity protein (1) . Interaction of vWF with platelets is essential for normal primary hemostasis, as shown by the prolonged bleed- ' Abbreviations used in this paper: VIII:C, Factor VIII procoagulant activity; CP, creatine phosphate; CPK, creatine phosphate kinase; EACA, e-aminocaproic acid; Kd, apparent dissociation constant; PMSF, phenylmethylsulfonyl fluoride; U, arbitrary unit of Factor VIII/vWF-related activities; Vo, void volume; vWD, von Willebrand disease; vWF, von Willebrand factor.
ing time in patients with von Willebrand disease (vWD) (1) and the Bernard-Soulier platelet defect (2) .
vWF promotes platelet adhesion to exposed subendothelium (2) but its role in platelet-to-platelet interaction, i.e., platelet aggregation, is not defined. Binding of vWF to specific platelet membrane sites can be induced by the antibiotic ristocetin (3) and, as more recently described, by thrombin (4, 5) and ADP (6) . Although platelet aggregation is observed under these circumstances (6, 7) , the functional significance and the direct role of vWF have not been determined. Ristocetin is a nonphysiologic agent, and its action is not dependent on active platelet metabolism as it occurs with fixed platelets and in the absence of divalent cations (3) . In the case of ADP and thrombin, both agents can activate platelets by vWF-independent pathways, as shown by normal aggregation in patients with severe vWD (8) . Therefore, a direct correlation between vWF binding and aggregation has not been established using these two agonists.
Removal of terminal sialic acid residues from human vWF results in direct binding to platelets and aggregation (9) . Similar results are observed with unmodified bovine and porcine vWF (10) , suggesting that a specific receptor for vWF may be available on the platelet membrane in the absence of other stimuli. However, possible structural differences between the native human molecule and asialo-human, or unmodified bovine and porcine vWF might be responsible for this interaction, and no evidence exists that normal human vWF can interact directly with normal platelets.
Recently, two families with a new bleeding disorder of similar characteristics have been reported independently and designated as "pseudo-vWD" (11) or "platelet-type vWD" (12) . In both instances, ristocetin-induced platelet agglutination was enhanced as in type IIB vWD (13) . However, there was evidence for a platelet abnormality, as shown by increased binding of normal vWF to patient platelets in the presence of ristocetin (11, 12) . Moreover, in pseudo-vWD plateletrich plasma was aggregated directly by human vWF (11) .
In these studies we demonstrate that normal human vWF induces platelet aggregation in platelet-type but not type IIB vWD, thus establishing the distinct nature of these two abnormalities. Accordingly, specific binding of native human vWF to platelets in the absence of any additional stimulus occurs only in platelet-type vWD. Aggregation and binding require similar vWF concentrations, suggesting that they are related.
METHODS
Patients. The patients with platelet-type vWD were one woman and three of her adult sons, all previously reported in detail (12) . The two unrelated patients with type IIB vWD were one man and one woman, both previously described (13) . Healthy adult volunteers from the hospital staff served as normal controls. Informed consent was obtained from all donors, and experiments were performed in accordance with the Declaration of Helsinki.
Sample collection and aggregation studies. Blood was collected by a two-syringe technique using polypropylene syringes and 19-gauge needles, and immediately transferred into polypropylene tubes containing 1/10th final volume of 3.8% trisodium citrate. For some experiments, blood was drawn using the same citrate concentration but with the addition of apyrase (grade III, Sigma Chemical Co., St. Louis, MO) to achieve a final concentration of 5 U/ml (based on 5'-ATPase activity). For preparation of washed platelets, blood was collected into 1/6th vol of standard acid-citratedextrose anticoagulant. Platelets were always handled in polypropylene containers. Platelet-rich plasma was prepared by centrifugation at 900 g for 75 s at room temperature (22°-25°C), and platelet-poor plasma by centrifugation at 4,000 g for 20 min at 4°C. Samples not immediately tested were stored at -70°C until used. Platelet counts were performed on a Coulter S Plus (Coulter Electronics, Hialeah, FL) or by phase-contrast microscopy. Measurements of platelet aggregation and ATP release were made in a Chrono-log Lumiaggregometer (Chrono-Log Corp., Havertown, PA), using 0.45 ml of patient platelet-rich plasma and 0.05 ml of 40 mg/ml myokinase-free luciferin-luciferase (Sigma Chemical Co.). In some experiments, rubber spacers (Chrono-Log Corp.) were placed under the aggregometer cuvet permitting the use of final volumes of 0.25 ml. The cuvet was maintained at 370C and the suspension stirred at 1,200 rpm with a magnetic stirrer. Release of ATP was quantitated by the addition of an internal ATP standard at the end of each experimental run. Rate of aggregation was determined from the maximal slope of the initial phase of aggregation, and calculated as change in percent light transmittance over time (A% T min-'). The transmittance of platelet-poor plasma was assigned a value of 100% and that of platelet-rich plasma 0%. In the case of washed platelets, appropriate substitutions of buffer for plasma were used for the platelet-poor plasma channel.
Preparations of washed platelet suspensions. Washed platelet suspensions for these studies were prepared by the albumin density gradient technique of Walsh et al. (14) , or by gel filtration of platelet-rich plasma through Sepharose 2B (Pharmacia Fine Chemicals, Piscataway, NJ). Washed platelets were finally maintained in modififed calcium-free Tyrode buffer containing 137 mM NaCl, 2.7 mM KCI, 0.42 mM NaH2PO4, 11.9 mM NaHCO3, 2 mM MgCl2, 5.5 mM glucose, and buffered to pH 7.3 with 25 mM Tris HCI or 10 mM Hepes.
Measurement of Factor VIII/vWF-related activities. The Factor VIII procoagulant activity (VIII:C) was measured by a modification of the partial thromboplastin time using activated Factor XI (8) . The ristocetin cofactor activity of vWF was measured using maximal rates of aggregation of formalin-fixed platelets (15) . vWF antigen was quantitated by the Laurell rocket electroimmunodiffusion technique using rabbit antibody (15) . All these measurements were expressed as arbitrary units (U) per milliliter. 1 U/ml corresponds to the amount of each of the Factor VIII/vWF-related activities present in 1 ml of a normal plasma pool.
Purification of vWF. Cryoprecipitate was prepared by the method of Pool et al. Sodium heparin (10 U/ml) was added to the plasma immediately after collection. The cryoprecipitate was resuspended at 370C in 200 ml of a buffer consisting of 20 mM Tris, 20 mM sodium citrate (tribasic), 20 mM e-aminocaproic acid (EACA), pH 7, containing 0.5 mM phenylmethylsulfonyl fluoride (PMSF), 10 U/ml Trasylol, and 10 U/ml sodium heparin. The redissolved cryoprecipitate was then adsorbed with Al(OH)3 (17) . The further purification steps were performed according to Newman et al. (18) Binding experiments. In a typical binding assay, platelets, at the indicated concentration, were incubated at room temperature with varying concentrations of 1251-vWF. In experiments performed with platelet-rich plasma, no stimulus was added to the platelets. Fibrinogen levels (23) in the patient plasmas were all within the normal range. In experiments performed with washed platelets, 0.25 NIH U/ml of purified a-thrombin (the generous gift of Dr. J. W. Fenton II) was used as a stimulus. In parallel mixtures, nonspecific binding was determined in the presence of a 25-to 50-fold excess of unlabeled vWF. After 30 min, 50 ,ul of the platelet suspension (in duplicate for each experimental point) was layered onto 400 ul of 20% sucrose in modified Tyrode buffer containing 2% bovine serum albumin (Sigma Chemical Co.), pH 7.3. 1-ml conical polypropylene tubes were used. The samples were centrifuged for 4 min at 13,000 g at room temperature in an Eppendorf microcentrifuge (Brinkmann Instruments, Westbury, NJ), the tips of the tubes containing the sedimented platelets were cut with a scalpel, and the platelet-associated radioactivity was measured. Characterization of this binding assay has been published in detail (5) . The line best fitted to the experimental points of each binding curve was obtained by means of a nonlinear fit program, and least-squares regression lines for double-reciprocal plots were obtained using proportionate standard error weighting (24) , using a desk-top computer model 85, (Hewlett-Packard Co., Palo Alto, CA). The 1251-vWF that became bound to platelets was analyzed by means of SDS-agarose electrophoresis after lysing the platelet pellets with 5% SDS for 15 min at 60°C, as previously described (5).
RESULTS
Characterization of purified vWF. The purified and radiolabeled '251-vWF used in these experiments appeared homogeneous on SDS-polyacrylamide gel electrophoresis under reducing conditions (Fig. 1) . Unreduced '251-vWF was composed of a series of multimers with a pattern similar to that observed in normal plasma (Fig. 8, lane 1) .
vWF-induced platelet aggregation. Platelets in platelet-rich plasma from all four patients with platelet-type vWD aggregated in response to the addition of highly purified vWF and single-donor cryoprecipitate (Fig. 2) . However, only one patient showed aggregation in response to normal plasma at the highest possible concentration used (0.225 ml into 0.5 ml final volume). There was no evidence of spontaneous aggregation of patient platelets upon prolonged (10 min) observation in the aggregometer under stirring con-FIGURE 1 Electrophoretic analysis of purified vWF. Direct autoradiography of purified vWF radiolabeled with 125I (1251_ vWF) after reduction with 2-mercaptoethanol and electrophoresis in a 5% acrylamide slab gel using a discontinuous buffer system. Cathode at the top. (Fig. 2) . No aggregation was observed in five normal volunteers or in the two patients with type IIB vWD under identical conditions (Fig. 2 ). All these experiments were performed within 3 h from blood sampling and with alternation of normal and patient samples in the aggregometer.
Platelet aggregation induced by vWF in patient platelet-rich plasma was dependent upon the presence of free divalent cations. EDTA, 2.5 mM, added before the addition of cryoprecipitate, blocked aggregation. Aggregation did, however, ensue upon the subsequent addition of excess calcium (5 mM), and was largely complete before clotting of plasma was observed. Magnesium at a 10 mM concentration had a minimal effect in overcoming the effect of 2.5 mM EDTA.
Washed platelets from normal donors were not aggregated by the addition of normal plasma cryoprecipitate. Washed patient platelets, on the contrary, exhibited aggregation in response to cryoprecipitate, but only at higher agonist concentrations than necessary in platelet-rich plasma and with a slower time course. Washed patient platelets suspended in modified Tyrode buffer containing CaCl2 (0, 0.1, 1.0, or 2.5 mM) showed little or no aggregation upon the addition of purified vWF (Fig. 3 A) . In contrast, when washed patient platelets were mixed with platelet-poor plasma (60% of final volume), strong and rapid aggregation was observed in response to purified vWF. The response was identical whether normal (Fig. 3 B) or patient (Fig. 3  C) AM ADP (Fig. 4, A and B) . In contrast, vWF-induced aggregation of the same platelet-rich plasma was completely unaffected by apyrase (Fig. 4, C and D) . The multimeric structure of the vWF added to the patient platelets was relevant in determining the aggregation response (Fig. 5) . When single-donor cryoprecipitate with intact multimeric structure (left panel, left lane) was added to patient platelets (1.2 U/ml ristocetin cofactor activity final concentration), strong aggregation resulted (right panel, cryoprecipitate). In contrast, commercial concentrate devoid of the larger multimers (left panel, right lane) added to these platelets (2.0 U/ml ristocetin cofactor activity final concentration) lacked comparable aggregating activity (right panel, commercial concentrate). The commercial concentrate failed to produce aggregation even at a final concentration of 4 U/ml ristocetin cofactor activity, and produced only very mild aggregation at 6 U/ml. Prior addition of the commercial concentrate, moreover, did not inhibit aggregation resulting from the subsequent addition of vWF possessing normal multimeric structure.
Platelet aggregation induced in platelet-rich plasma by both cryoprecipitate and purified vWF was concentration dependent. Both the rate and extent of platelet aggregation increased with increasing concentrations of vWF, until a plateau was reached. When the maximal rate of aggregation was plotted against the final concentration of vWF in the mixture (measured as ristocetin cofactor activity), a dose-response curve was obtained (Fig. 6) . The apparent dissociation constant (Kd) of the vWF-platelet interaction was estimated from double-reciprocal plots of the aggregation data (Fig. 6) . These values appeared of the same order of magnitude when either cryoprecipitate vWF were used (Table I) .
Specific binding of 125I-vWF to unstimulated platelets. When '25I-vWF was added in increasing concentrations to the platelet-rich plasma of two patients with platelet-type vWD, saturable binding was observed in the absence of any other stimulus (Fig. 7 A) (Fig. 7 A) . The (Fig. 6 ), specific binding was also plotted against the concentration of added '25I-vWF expressed as ristocetin cofactor activity (Fig. 7 B) . The apparent Kd derived from double-reciprocal plots of the experimental binding data (Fig. 7 B) was of the same order of magnitude as the apparent Kd derived from aggregation dose-response curves (Table I ).
All multimers present in the '251-vWF added to the platelet-rich plasma (Fig. 8, lane 1) became associated with platelet-type vWD platelets, as shown by electrophoretic analysis of bound material following solubilization of platelet pellets (Fig. 8, lane 3) . No multimers were seen in the lysates of control platelets under the same conditions (Fig. 8, lane 2) .
Binding of 125I-vWF to thrombin-stimulated washed platelets. Thrombin-stimulated washed platelets from two patients with platelet-type vWD bound '25I-vWF in a manner similar to normal platelets (Fig. 9) (Fig. 9) , was about an order of magnitude lower than the apparent Kd for binding to platelets in patient platelet-rich plasma without added thrombin (Table II) . In the two patients with type IIB vWD, the thrombin-induced binding of vWF to platelets was also similar to normal (Table II) agreement with this hypothesis, we found that addition of 1251-vWF to platelet-rich plasma from patients with platelet-type vWD resulted in specific and saturable binding independent of any additional stimulus. Specificity was proven by using a homogeneous vWF preparation and by performing the experiments directly in platelet-rich plasma. This assured that other plasma proteins known to interact with platelets, and notably (29) . The use of proportionate standard error weighting in the linear regression analysis (24) receptor abnormality presumably present on platelettype vWD platelets is not shared by type IIB vWD, thus confirming the distinct pathogenesis of these two disorders. Thrombin stimulation of platelets from patients with platelet-type vWD resulted in specific and saturable binding of vWF approximately threefold greater than that observed when vWF was added to plateletrich plasma without any additional stimulus. The Kd derived from double-reciprocal plots were approximately one order of magnitude smaller than those derived from binding curves generated with platelet-rich plasma in the absence of added thrombin. In this regard, experimental evidence has recently been obtained to show that the vWF-binding site induced by thrombin and ADP is different from that induced by ristocetin (30) . Therefore, the possibility exists that the thrombin-induced binding site is also different from the abnormal one present on unstimulated platelets from patients with platelet-type vWD, thus explaining the different binding characteristics. Thrombin-induced binding was similar to normal in both platelettype and type IIB vWD, thus suggesting that the vWFbinding site involved in this interaction is normal in both disorders.
In recent studies, Fujimoto and Hawiger (6) and Ruggeri et al. (30) have shown that ADP can induce the binding of vWF to human platelets. Thrombininduced binding of vWF, moreover, is inhibited in the presence of ADP-consuming systems (4, 30) . In platelet-type vWD, thrombin-induced binding of vWF was inhibited both by the ADP-splitting enzyme, apyrase, and the ADP-converting system, CP/CPK. This finding is consistent with the concept that the mechanism of thrombin-induced vWF binding is normal in these patients. In contrast to thrombin-induced binding, ADP was not required for the characteristic interaction of vWF with platelet-type vWD platelets in unstimulated platelet-rich plasma. This was demonstrated both with respect to the binding of 1251-vWF and to the aggregation of platelets in response to vWF. Such results indeed suggest that the ADP-independent binding of vWF to these platelets occurs at a different site than the one involved in thrombin-and ADP-induced binding. The latter has been recently associated with the glycoprotein IIb/IIIa complex (30) .
The presence of free calcium ions was necessary for vWF-induced aggregation in the platelet-rich plasma of these patients. Inhibition of aggregation by EDTA could be overcome by calcium, but much less effectively by magnesium. This calcium dependence for platelet aggregation (and secretion) induced by vWF in platelet-type vWD stands in contrast to the calciumindependent agglutination of normal platelets induced by vWF in the presence of ristocetin (31) . Washed patient platelets suspended in buffer containing a wide range of calcium concentrations (0-2.5 mM) failed to aggregate in response to purified vWF when plasma was not added. Adjustment of pH in the buffer to that observed in mixtures of washed platelets and plateletpoor plasma did not alter this result. It seems, therefore, that a plasma cofactor other than calcium or pH is involved in vWF-induced aggregation of platelettype vWD platelets. Normal plasma, as well as the patients' own plasmas, were equally effective in this regard.
Direct autoradiographic studies with '25I-vWF showed that all multimeric forms of vWF bind to platelet-type vWD platelets in platelet-rich plasma. However, commercial concentrate deficient in the larger vWF multimers was relatively ineffective in inducing aggregation of these platelets. Therefore, it appears possible that although even the smaller vWF multimers bind, they are less effective in promoting aggregation of platelet-type vWD platelets. It is of interest that ristocetin also induces binding of all vWF multimers to normal platelets (30) , although it is primarily the larger multimers that are thought to be involved in ristocetin-induced platelet agglutination (32, 33) .
The existence of available binding sites for vWF on unstimulated normal human platelets can be inferred from the specific binding of human asialo-vWF (9) or unmodified bovine and porcine vWF (34) . However, these binding sites are normally not occupied by unmodified human vWF, suggesting that the affinity for the intact human molecule is too low for any significant interaction to occur at physiological ligand concentrations. In platelet-type vWD, however, a congenital structural change in or near the binding site might be responsible for the observed interaction of platelets with unmodified human vWF in the absence of other stimuli.
Patients with platelet-type vWD and pseudo-vWD may show borderline thrombocytopenia (11, 12) , and consistently lack the larger vWF multimers in plasma (11, 12) . The apparent Kd derived from aggregation dose-response curves and binding isotherms show that a relatively high concentration of normal vWF (>1.5 U/ml of ristocetin cofactor activity) is necessary for inducing aggregation at half-maximal rate. Since the plasma levels of ristocetin cofactor activity in these patients are usually well below these values, presumably due to absorption of vWF onto the abnormal platelet membrane, platelet consumption in vivo may be a selflimiting phenomenon. Removal of the larger vWF multimers from plasma without platelet aggregation may explain the prevalence of a bleeding rather than thrombotic tendency in these patients. Similar considerations might be relevant in deciding the amount of plasma or plasma derivatives to be used for therapeutic purposes. Achieving plasma levels of vWF sufficient to stop or prevent bleeding, and yet below the critical concentrations that induce aggregation, might help prevent severe thrombocytopenia in these patients.
